Schedule of Pharmaceutical Benefits - 1 September 2021 update

PBAC

1 September 2021 - The September 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The September issue of the Schedule includes a few new/revised listings:

  • Abiraterone acetate (Zytiga) - restriction change
  • Adrenaline (Anapen) - new formulation
  • Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides (Essential Care Jr) - new formulation
  • Brentuximab vedotin (Adcetris) - new indication
  • Cariprazine hydrochloride (Reagila) - new medicine
  • Deferasirox (Deferasirox Juno) - new formulation
  • Enzalutamide (Xtandi) - restriction change
  • High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (K. Yo) - new formulation
  • Lacosamide (Vimpat) - new indication
  • Obeticholic acid (Ocaliva) - new medicine
  • Semaglutide (Ozempic) - new indication
  • Teduglutide (Revestive) - restriction change
  • Vedolizumab (Entyvio) - new formulation

Read Summary of PBS changes

Michael Wonder

Posted by:

Michael Wonder